ZYDUS LIFESCIENCES LTD Q4 RESULTS
![Q4 results: Stable costs boost India Inc. profits](https://img.etimg.com/thumb/msid-111014295,width-100,height-75,resizemode-4/wealth/invest/q4-results-stable-costs-boost-india-inc-profits.jpg)
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
![Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore](https://img.etimg.com/thumb/msid-110311488,width-100,height-75,resizemode-4/markets/stocks/earnings/eris-lifesciences-q4-results-net-profit-jumps-over-29-to-rs-80-crore.jpg)
Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore
The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.
![Hot Stocks: Brokerage view on Phoenix Mills, Anupam Rasayan; CLSA downgrades Delhivery](https://img.etimg.com/thumb/msid-110290313,width-100,height-75,resizemode-4/markets/stocks/news/hot-stocks-brokerage-view-on-phoenix-mills-anupam-rasayan-clsa-downgrades-delhivery.jpg)
Hot Stocks: Brokerage view on Phoenix Mills, Anupam Rasayan; CLSA downgrades Delhivery
CLSA downgraded Delhivery to underperform, Jefferies raised Zydus Life target, and Anupam Rasayan had balance sheet concerns. Citigroup recommended buying Phonix Mills.
![Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC](https://img.etimg.com/thumb/msid-110244356,width-100,height-75,resizemode-4/markets/stocks/news/q4-results-this-week-itc-ongc-sun-pharma-nykaa-ircon-international-and-irfc.jpg)
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
![Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore](https://img.etimg.com/thumb/msid-110214652,width-100,height-75,resizemode-4/markets/stocks/earnings/zydus-lifesciences-q4-results-drug-makers-posts-threefold-yoy-jump-in-net-profit-to-rs-1182-crore.jpg)
Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
![Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr](https://img.etimg.com/thumb/msid-110213549,width-100,height-75,resizemode-4/markets/stocks/earnings/zydus-q4-results-net-profit-surges-4-fold-to-rs-1182-crore-revenue-at-rs-5534-cr.jpg)
Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr
Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Apar Industries shares zoom 8% after company reports Q4 results, announces Rs 51 dividend
Apar Industries recorded a fresh 52-week high on Tuesday apparently propelled by its Q4 revenue growth of 9% YoY. Its PAT, however, declined 3% YoY. The stock has zoomed 208% in the last one year.
Zydus Wellness shares rally nearly 4% after reporting PAT at Rs 150 crore; declares Rs 5 dividend
Zydus Wellness shares surged 3.8% on BSE, reaching a new 52-week high at Rs 1,750.20 following a 4% YoY rise in Q4 FY24 profit after tax to Rs 150.3 crore. The board announced a dividend of Rs 5 per share, with the record date set for July 19.
Q4 results this week: Zomato, Airtel, M&M among 501 companies set to announce earnings this week
Some notable companies that will announce their earnings this week include Varun Beverages, Zomato, Airtel, Siemens, Power Finance Corp, Mahindra and Mahindra, HAL, and JSW Steel, among others. Overall, around 501 companies are set to release their quarterly numbers this week.
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
Supriya Lifesciences Q3 Results: Net profit triples to Rs 30 crore
Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points.
Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian pharma companies have come a long way.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore
Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.
Zydus Q2 Results: Profit jumps on strong domestic, US demand
India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Zydus Lifesciences Q1 Results: Net profit doubles to Rs 1,087 crore, revenue jumps 30%
US business grew by 57% YoY at Rs 2454 crores. India branded formulations grew by almost 12%, excluding impact of NLEM related price cut affecting some key products
Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Q1 earnings: 26 companies that may report over 100% jump in profit
Domestic brokerage Motilal expects Nifty earnings to grow 25% YoY in Q1. Oil and gas sector may report a 3x surge in profit YoY underpinned by the improvement in marketing margins of OMCs. Auto sector’s earnings may surge 11x YoY during the quarter on a low base.
Load More